BioSpace News Archive

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry of Health, Pharmaceuticals and Medical Devices Agency (MoH) to recruit up to twenty additional patients into the Phase II trial of its lead drug LSALT peptide (Metablok), targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.

Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced the appointment of David M. Goldstein, Ph.D., to its Board of Directors.

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody

Proceeds will support development of novel myeloid checkpoint inhibitors including its clinical program IO-202, a first-in-class LILRB4 antagonist antibody in blood cancers and solid tumors, and its preclinical programs IO-108 and IO-106, targeting LILRB2 and LAIR1 respectively

Proscia®, a leading provider of digital and computational pathology solutions, and Unilabs, a leading international provider of diagnostic services, have established a strategic partnership to accelerate the adoption of artificial intelligence (AI) in routine pathology practice

Agilent Technologies Inc. (NYSE: A) announces that Octagon Therapeutics has been awarded an Agilent Golden Ticket at LabCentral

Curevo Vaccine, a clinical-stage biopharmaceutical company combining excellence in protein and adjuvant biology to develop new generation sub-unit vaccines of global importance, announced today that approval was granted to move forward with a Phase 1b pediatric clinical trial in South Africa to evaluate the safety, efficacy, and immunogenicity of its non-live investigational vaccine, CRV-101,

Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313, the phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX ® ), nivolumab (OPDIVO ® ) and ipilimumab (YERVOY ® ) versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC), has completed enrollment.

Can-Fite BioPharma Ltd. announced that the six existing distribution agreements it has signed for its advanced stage drug candidates Piclidenoson and Namodenoson in select territories have remaining potential milestone payments of up to approximately $130 million plus double digit royalties on net sales following regulatory approval.

Bristol Myers Squibb (NYSE:BMY) today announced that the company will host a virtual Investor Event on Friday, April 23, 2021 at 10:30 a.m. ET to discuss data from the POETYK PSO-1 and POETYK PSO-2 Phase 3 trials of deucravacitinib in patients with moderate-to-severe psoriasis, which will be presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX).